Reach Us +44-1474-556909
Psychotropic Drugs And Pregnancy | 96191
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

7th European Biopharma Congress

Prague, Czech Republic

33rd World Congress on Pharmacology

Barcelona, Spain
Share This Page

Psychotropic drugs and pregnancy

6th European Biopharma Congress

Bimal Roy Krishna

Touro University, USA

Keynote: Clin Pharmacol Biopharm

DOI: 10.4172/2167-065X-C1-027

During pregnancy psychiatric disorder may occurs requiring appropriate therapy. These conditions may also be preexisting which require careful diagnosis and monitoring. While it is essential to treat such conditions, pregnancy limits the use of psychotropic drugs due to potential adverse fetal outcomes and possibly teratogenicity. Understandably improvement of the disease state may provide benefit to the developing fetus. Recent studies show that up to 20% of women suffer from mood or anxiety disorders during pregnancy. Depression and anxiety during pregnancy have been associated with a variety of adverse pregnancy outcomes. Women who suffer from psychiatric illness during pregnancy are less likely to receive adequate prenatal care and are more likely to abuse alcohol, tobacco, and other substances known to adversely affect pregnancy outcomes. IUGR, low birth weight and fetal growth retardation in children born to depressed mothers have been documented. Preterm delivery is another potential complication with an increased risk of pre-eclampsia, operative delivery, and infant admission to a special care nursery for a variety of conditions including respiratory distress, hypoglycemia, and prematurity. A number of non-pharmacological options are available including cognitive behavioral and interpersonal psychotherapy. Nevertheless a considerable percentage of patients will need pharmacological intervention keeping in mind that a number of psychotropic medications may treat more than one condition. This presentation covers maternal mental illness and pregnancy outcome and current therapeutic interventions and guidelines.

Bimal Roy Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. He also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over seven years. He has contributed to numerous publications and is a Member of a number of organizations including Fellow-American College of Clinical Pharmacology. His research background is in Maternal and Neonatal Pharmacology, specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model. Complementary and Alternative Medicine is another area of his interest.

E-mail: [email protected]